Lantern Pharma Inc.
NASDAQ:LTRN

Watchlist Manager
Lantern Pharma Inc. Logo
Lantern Pharma Inc.
NASDAQ:LTRN
Watchlist
Price: 3.8 USD 1.6% Market Closed
Market Cap: 41m USD

Lantern Pharma Inc.
Investor Relations

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. The company is headquartered in Dallas, Texas and currently employs 14 full-time employees. The company went IPO on 2020-06-11. The firm is focused on leveraging artificial intelligence (AI), machine learning and genomic data to streamline the drug development process and to identify the patients, which benefits from its targeted oncology therapies. The Company’s therapies portfolio consists of small molecule drug candidates and new compounds, which it is developing with the assistance of its AI platform and its biomarker driven approach. The Company’s AI platform, RADR uses big data analytics, including combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data, and machine learning. The Company’s data-driven, gnomically targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy, which identifies, rescues or develops, and advances potential small molecule drug candidates.

Show more
Loading

Earnings Calls

2025 Q3
Jan 30, 2025
Show Transcript
Previous
Next
Welspun Living's steady growth and revised EBITDA guidance amid external challenges
2025 Q3
Jan 30, 2025

In Q3 FY '25, Welspun Living reported revenues of INR 2,528 crores, up 3% year-on-year, and an EBITDA margin of 12.6%. Year-to-date, they achieved a growth of 11.7%, aligning with their guidance of 10-12%. Despite rising costs affecting margins, including a freight increase of 40% and currency depreciation effects, they anticipate full-year EBITDA to be revised to 14%. The company's focus on domestic and international markets continues, with expectations to reach INR 15,000 crores by FY '27, supported by thriving segments like Advanced Textiles and a robust global brand portfolio.

Show Full Analysis

Management

Mr. Panna Sharma PH.D.
President, CEO & Director
No Bio Available
Mr. David R. Margrave
CFO & Secretary
No Bio Available
Dr. Kishor Gopaldas Bhatia Ph.D.
Chief Scientific Officer & Scientific Consultant
No Bio Available
Nicole Leber
Investor Relations Associate, Finance & Administrative Coordinator
No Bio Available
Dr. Peter L. Nara D.V.M., M.S., Ph.D.
Co-Founder & Advisor
No Bio Available
Mr. Ernest Kitt B.S., M.S
Head of Clinical Operations
No Bio Available
Dr. Marc C. Chamberlain M.D.
Chief Medical Officer of Starlight Therapeutics
No Bio Available

Contacts

Address
TEXAS
Dallas
1920 Mckinney Avenue, 7th Floor
Contacts